Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Overview of attention for article published in Journal for Immunotherapy of Cancer, May 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

So far, Altmetric has seen 47 X posts from 30 X users, with an upper bound of 62,697 followers.

Predicting response to checkpoint inhibitors in #Melanoma beyond PD-L1 and mutational burden #Cancer https://t.co/CAXDFJbt9H

RT @sitcancer: #JITC Research: Predicting response to checkpoint #inhibitors in #melanoma beyond PD-L1 and mutational burden https://t.co/u…

This is bound to be a hot topic at #ASCO18: looking at #biomarkers beyond PD-L1. https://t.co/EKlRQgAxBo

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 43 additional X posts.